This is how SVFC will make money! And it is already generating royalities : )
Technology Licensing
IntelliCell will license its suite of technology and protocol to physicians or surgery centers for use among their patients.
ICBS Lab Technician runs the process ensuring quality control and GMP & GLP compliance.
Opportunities:
Orthopedics: Over 1 Million Hip and knee replacements, 600,000
back procedures performed annually in the U.S. where SVFs could
potentially mitigate the need for surgery.
Sports Medicine: A $1.3B addressable market and a key corporate
focus with meaningful partnerships already secured.
Periodontal Disease: A $6B addressable market; IntelliCell has recently completed case studies using SVFs in the treatment of gum recession showing no need for grafting
SPORTS MEDICINE
Sports Medicine is a key strategic focus for IntelliCell
as it seeks to build broad brand awareness among
both professional and non-professional athletes.
IntelliCell’s efforts led by Dr. James Andrews of the
Andrews Sports Medicine and Orthopedic Centers.
Planned multi-center clinical study exploring SVF’s
impact on osteoarthritis of the knee.
MARKET OPPORTUNITY
17,000 Professional Athletes in the U.S.
50,000 NCAA Division I Athletes in the U.S.
Millions of amateur athletes and aging boomers
REVENUE MODEL FOR LICENSING
$150,000 in upfront licensing fees for
equipment, installation, and training.Yields high margin revenues for IntelliCell. $1,000 in per procedure fees to IntelliCell.
Two procedures per week per lab generates $100,000 in annual revenues for IntelliCell.
IntelliCell estimates 100 labs will be operational by year-end 2013.
Licensing Partners:
IntelliCell has licensed its Technology to International partners for large upfront payments and ongoing royalties.
SECURED PARTNERS
Licensed by RegenaStem in Canada (operating as IntelliCell
BioSciences of Canada) for $500,000 upfront and a 30% share of
revenues. Licensed by Cell-Innovations, Pty Limited in Australia for $700,000 upfront and a 12.5% share of revenues.
PROSPECTIVE PARTNERS
Middle East led by Saudi Arabia
Thailand
Malaysia
Indonesia
ACTIVE PARTNERSHIP DISCUSSIONS
Wound Care: The Global wound care market generated $6.2B in 2010.
Over the course of the next decade, demand for advanced wound care will increase due to an increasing prevalence of chronic wounds as diabetes and obesity rates increase.
Heart Disease: Cytori, an IntelliCell peer that harvests stem cells from adipose tissue using enzymes, is sponsoring three European clinical trials to evaluate the use of adipose-derived stem and regenerative cells in the treatment of acute myocardial infarction and chronic myocardial ischemia and recently received FDA approval for IDE.
Adipose stem cell heart attack trial data published in the Journal of American College of Cardiology in January 2012.
IntelliCell is in discussion with several partners who may desire a substantially similar solution that leverages IntelliCell technology.
Centers of Excellence
Centers of Excellence are IntelliCell
managed locations where patients can receive SVF treatments.
First Center to open in April 2012 offering cosmetic and dermatologic procedures. Centers of Excellence receives $10,000 per patient per procedure versus $1,000 in the lab
sales model. Centers of Excellence receives $2,500 per
procedure when other physicians utilize the facility.
PLANNED CENTERS
Beverly Hills, CA
Miami, FL
Houston, TX
SVF Cryo-Storage
IntelliCell’s Cryo-Storage Service will create a large stream of high margin recurring revenues. $500 for initial collection.
$200 per dose per year for storage. $1,000 for removal from storage and shipment to physicians for use by patient.
OPPORTUNITY
500,000 liposuction procedures performed annually, an ideal source of customers who have ready access to adipose tissue.
Examining acquisitions and joint ventures opportunities with several prominent cryo-storage companies.
